Active substanceCefazolinCefazolin
Similar drugsTo uncover
  • Zolin
    powder w / m in / in 
  • Intrazolin
    powder w / m in / in 
  • Lizolin
    powder w / m in / in 
    FARMGID CJSC     Russia
  • Nacef®
    powder w / m in / in 
    PREBAND PFC, LLC     Russia
  • Orpin®
    powder w / m in / in 
  • Cesolin
    powder w / m in / in 
    Lupine Co., Ltd.     India
  • Cefazolin
    powder w / m in / in 
  • Cefazolin
    powder w / m in / in 
  • Cefazolin
    powder w / m in / in 
    Company DEKO, LLC     Russia
  • Cefazolin
    powder w / m in / in 
  • Cefazolin
    powder w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Cefazolin
    powder w / m 
    BIOCHEMIST, OJSC     Russia
  • Cefazolin
    powder w / m in / in 
    KRASFARMA, JSC     Russia
  • Cefazolin
    powder w / m in / in 
    OMELA, LTD.     Russia
  • Cefazolin
    powder w / m in / in 
  • Cefazolin
    powder w / m in / in 
    LEKKO, ZAO     Russia
  • Cefazolin
    powder w / m in / in 
  • Cefazolin
    powder w / m 
    KRASFARMA, JSC     Russia
  • Cefazolin
    powder w / m in / in 
    RUZFARMA, LLC     Russia
  • Cefazolin
    powder w / m in / in 
  • Cefazolin
    powder w / m in / in 
  • Cefazolin Sandoz
    powder w / m in / in 
    Sandoz GmbH     Austria
  • Cefazolin Elf
    powder w / m in / in 
    Elfa Laboratories     India
  • Cefazolin-AKOS
    powder w / m in / in 
    SYNTHESIS, OJSC     Russia
  • Cefazolin-Ferein®
    powder w / m in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Cefazolin-Ferein®
    powder w / m in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Cefamesin®
    powder w / m in / in 
  • Dosage form: & nbsppowder for solution for intravenous and intramuscular administration
    Composition:
    Each vial contains 1.085 g of cefazolin sodium, which corresponds to 1 g of cefazolin.
    Description:The powder is white, hygroscopic.
    Pharmacotherapeutic group:Antibiotic-cephalosporin
    ATX: & nbsp

    J.01.D.B.04   Cefazolin

    Pharmacodynamics:

    Cefazolin is a cephalosporin antibiotic of the 1st generation. It is bactericidal.

    It has a wide spectrum of antimicrobial action. It is active both against Gram-positive (Staphylococcus spp., Not producing and producing penicillinase, Streptococcus spp., Pneumococcus, C.diphtheriae, B.antracis), and Gram-negative microorganisms (N.Meningitidis, N. gonorrhoeae, Shigella, Salmonella, E. Coli, Klebsiella).

    It is also active against Spirochaetaceae and Leptospiraceae.

    The drug is not effective against P. aeruginosa, indolpositive strains of Proteus, M. tuberculosis, anaerobic microorganisms.

    Pharmacokinetics:With intramuscular and intravenous administration, the drug is rapidly absorbed and distributed in tissues and body fluids, the maximum concentration in the blood reaches after 1 hour and remains in the therapeutic concentration of 8-12 hours, easily penetrates the placental barrier, into the synovial, pleural and peritoneal exudates. It is allocated mainly by the kidneys, creating high concentrations in the urine.
    Indications:
    Cefazolin sodium salt is used for infectious and inflammatory diseases caused by susceptible pathogens (sepsis, peritonitis, endocarditis, respiratory tract infections, genito-urinary tract, including syphilis and gonorrhea, infections of the bones and joints), as well as for the prevention of postoperative complications .
    Contraindications:

    Hypersensitivity to cephalosporins and other beta-lactam antibiotics.

    Pregnancy and lactation. If necessary, breast-feeding is stopped.

    Do not appoint a newborn.

    Carefully:With caution, the drug is prescribed to patients with diseases of the gastrointestinal tract (especially with colitis).
    Dosing and Administration:

    It is established individually taking into account the severity of the course and localization of the infection, the sensitivity of the pathogen.

    The drug can be administered intramuscularly, intravenously (struino or drip).

    Average daily dose for adults is 1 g; the frequency of administration is 2 times a day. The maximum daily dose is 6 g; the frequency of administration can be increased up to 3-4 times a day.

    For the prevention of postoperative infectious complications prescribe 1 g of cefazolin 30 minutes prior to surgery; 0.5-1 g during the operation and 0.5-1 g every 6-8 hours during the day after the operation.

    Average daily dose for children is 20-50 mg / kg body weight; In severe infections, the dose can be increased to 100 mg / kg per day.

    The average duration of treatment is 7-10 days.

    In patients with impaired renal function The dosage regimen of cefazolin is set taking into account the values ​​of creatinine clearance. With SC greater than 55 ml / min (or serum creatinine less than 1.5 mg%), the dosing regimen, as a rule, does not require correction. When QA 35-54 ml / min (serum creatinine less than or 1,6-3% mg) single dose may remain unchanged, however, should increase the interval between administrations to 8 hours.

    With CC 11-34 ml / min (or serum creatinine 3.1-4.5 mg%) single dose should be reduced by 2 times; intervals between administrations are 12 hours. With SC less than 10 ml / min (or serum creatinine more than 4.6 mg%), one-half of the usual dose is prescribed every 18-24 hours. All recommendations for prescribing low doses are applied after an initial loading dose corresponding to the severity of the infection is established.

    For intramuscular injection, the drug is dissolved in 4-5 ml of water for injection, isotonic sodium chloride solution or 0.25-0.5% solution of novocaine.

    For intravenous drip, the drug is dissolved in 100 250 ml of isotonic sodium chloride solution or 5% glucose solution; the injection is carried out for 20-30 minutes (the rate of administration is 60-80 drops per minute).

    For intravenous fluid administration, a single dose of the drug is diluted in 10 ml of isotonic sodium chloride solution and injected slowly for 3-5 minutes.

    Side effects:

    When treating cefazolin sodium salt, it is possible to develop allergic reactions in the form of skin rash, itching, eosinophilia, Quincke's edema, arthralgia, anaphylactic shock. In these cases, it is necessary to stop the drug administration and conduct desensitizing therapy.

    In patients with kidney disease, when treated with large doses of cefazolin (6 g), there may be signs of kidney failure. In these cases, the dose of the drug is reduced and the treatment is controlled by the dynamics of urea nitrogen and creatinine in the blood. Gastrointestinal disorders (anorexia, diarrhea, nausea, vomiting, pseudomembranous colitis, transient increase in liver transaminase activity) are possible. With long-term treatment, dysbacteriosis, superinfection caused by antibiotic-resistant strains, candidiasis can develop. When intramuscular injection of the drug in rare cases, there is phlebitis, soreness at the injection site.

    On the part of the hematopoiesis system: neutropenia, leukopenia, thrombocytopenia.

    Interaction:The drug is not recommended to be used simultaneously with oral anticoagulants and diuretics (furosemide, ethacrynic acid).
    Special instructions:

    When using cefazolin, positive direct and indirect Coombs probes may appear.

    With cefazolin, a false positive reaction to glucose in the urine is possible.

    During pregnancy, the drug is prescribed only for life indications.

    During lactation apply with caution.

    The safety of the drug in preterm infants and children of the first month of life is not established.

    Form release / dosage:
    Powder for solution for injection.
    Packaging:
    For 1.0 g in vials.
    Storage conditions:Store at room temperature. Keep out of the reach of children.
    Shelf life:3 years. Do not use after the time specified on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N013048 / 01-2001
    Date of registration:26.11.2008
    Expiration Date:Unlimited
    The owner of the registration certificate:LDP - Laboratories TorlanLDP - Laboratories Torlan Spain
    Manufacturer: & nbsp
    Representation: & nbspLaboratory Thorlan Laboratory Thorlan France
    Information update date: & nbsp26.10.2017
    Illustrated instructions
      Instructions
      Up